Bristol-Myers Squibb Co. (BMY) Shares Sold by Kidder Stephen W
Kidder Stephen W decreased its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 2.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,200 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Kidder Stephen W’s holdings in Bristol-Myers Squibb were worth $603,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in BMY. Jolley Asset Management LLC increased its position in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Bristol-Myers Squibb during the second quarter worth approximately $163,000. Solaris Asset Management LLC increased its position in shares of Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 75 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,353 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 12 shares in the last quarter. Finally, Madrona Financial Services LLC purchased a new position in shares of Bristol-Myers Squibb during the second quarter worth approximately $200,000. Institutional investors and hedge funds own 72.91% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.957% on Thursday, reaching $56.465. The company had a trading volume of 6,622,492 shares. Bristol-Myers Squibb Co. has a 52-week low of $55.02 and a 52-week high of $77.12. The company’s 50-day moving average is $59.04 and its 200-day moving average is $67.58. The company has a market capitalization of $94.35 billion, a PE ratio of 33.020 and a beta of 0.61.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The company had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. During the same period last year, the business posted $0.53 EPS. The company’s revenue was up 17.2% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb Co. will post $2.62 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.
A number of brokerages have commented on BMY. SunTrust Banks Inc. downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $86.00 to $68.00 in a report on Friday, August 5th. Berenberg Bank reiterated a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, July 12th. Deutsche Bank AG reiterated a “hold” rating on shares of Bristol-Myers Squibb in a report on Wednesday, June 15th. Morgan Stanley downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $63.00 target price for the company. in a report on Friday, August 5th. Finally, Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price target on the stock in a research note on Monday, July 25th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $69.64.
In related news, Director Lamberto Andreotti sold 23,200 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the sale, the director now directly owns 380,099 shares in the company, valued at $28,298,370.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.24% of the stock is owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.